Drugs / Unconjugated belantamab antibody
Unconjugated belantamab antibody
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05714839 | Jun 2023 → Aug 2028 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Unconjugated belantamab antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05714839 ↗ |
| Modality | Protein / enzyme biologic | “Unconjugated belantamab antibody” NCT05714839 ↗ |